Open an account

Biote

BTMD · NASDAQ

$1.07−$0.01 (−0.93%)TodayMarket closed ·
Prev close $1.08

About BTMD

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 223 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

Employees
223
Headquarters
Irving, Texas
Listed
Mar 2, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
haymakeracquisition.com

BTMD key statistics

Market cap
38.44M
Price-earnings ratio
9.82
Dividend yield
—
Average volume
128.82K
Volume
42.56K
Open price
$1.06
High today
$1.11
Low today
$1.05
52 Week high
$3.26
52 Week low
$1.00

Biote (BTMD) at a glance

Biote (BTMD) last traded at $1.07, with a market cap of 38.44M and a price-to-earnings ratio of 9.82.

Today the stock has traded between $1.05 and $1.11. The current price is 2.4% above the day's low and 3.6% below its high.

Volume so far is 42.56K shares, below the average of 128.82K shares a day.

Over the past year Biote has ranged from $1.00 to $3.26, and now sits 3% of the way up that range.

Biote met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.21 per share against an estimate of $0.0408.

The average analyst price target is $2.66, 149.0% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 7 analystsAvg $2.66
Low
$1.51
Now
$1.07
High
$4.20

BTMD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 216.6% on average.

  1. Q3 FY24: reported $0.33 per share against an estimate of $0.0918
  2. Q4 FY24: reported $0.10 per share against an estimate of $0.102
  3. Q1 FY25: reported $0.37 per share against an estimate of $0.0663
  4. Q2 FY25: reported $0.18 per share against an estimate of $0.0646
  5. Q3 FY25: reported $0.22 per share against an estimate of $0.0476
  6. Q4 FY25: reported $0.06 per share against an estimate of $0.051
  7. Q1 FY26: reported $0.06 per share against an estimate of $0.0485
  8. Q2 FY26: reported -$0.21 per share against an estimate of $0.0408

BTMD news

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseBusiness Wire

    Biote Reports Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

  • Press releaseBusiness Wire

    Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

  • Press releaseBusiness Wire

    Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

  • Press releaseBusiness Wire

    Biote Reports First Quarter 2026 Financial Results

Similar companies

Companies in the same industry as Biote

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.